Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to May 1996

May 1996


European Immune Boosting Therapies

Isoprinosine is approved by almost every regulatory agency in the world except the U.S. Food & Drug Administration (FDA).

On June 21, 1990, The New England Journtal Of Medicine published findings that isoprinosine slows the progression of HIV infection! This report was one of hundreds of published studies showing that isoprinosine boosts immune function in cancer patients, persons infected with HIV, and healthy people.

In 1985, The Foundation recommended that HIV infected people take isoprinosine to slow the decline in immune function that leads to full-blown AIDS. Isoprinosine can be purchased from various "Buyers Clubs" that supply Alzheimer's patients and HIV-infected people with drugs that haven't yet been approved by the FDA.

Immune boosting drugs work best when taken on an alternative dosing schedule, i.e. isoprinosine works best when taken two months on, two months off.

Here is an immune boosting schedule for healthy and immune compromised patients to consider:

Isoprinosine Therapy: Take 2,000 mg. to 3,000 mg. daily for two months. Repeat every other two months.

After completing two months of isoprinosine therapy take one round of:

  • Biostim Therapy: Three month dosing schedule as follows:
  • 2 tablets daily for eight days. Then stop for three weeks.
  • 1 tablet daily for eight days. Then stop for three weeks.
  • 1 tablet daily for eight days. Then stop for nine months.

After completing Biostim Therapy, we suggest a two month regimen of:

Thymic Immune Factors produces mechanisms of immune enhancement similar to isoprinosine. For optimal immune maintenance, we suggest that isoprinosine be taken for two months, then take a two month break and start a two-month course of Thymic Immune Factors. After another two month break, start another two month course of isoprinosine.


The FDA has approved four toxic anti-viral drugs to slow the progression of HIV infection. These drugs are AZT, ddI, ddC, and 3TC. There are additional cytotoxic anti-viral drugs the FDA will be approving soon.

There is enthusiasm in some parts of the AIDS community that various combinations of these anti-viral drugs could enable those with HIV infection and clinically diagnosed AIDS to maintain long-term remissions. Newly published studies are showing that various combinations of these anti-viral drugs work better than AZT alone.

Recent Studies

The two most recent studies indicate that a combination of AZT and 3TC, along with one of the new relatively non-toxic protease inhibitors may be the ideal combination for AIDS patients to try first.

From a technical standpoint, the belief that these anti-viral combinations will be able to put HIV infections into long-term remission seems almost too good to be true. In fact, there is an erie resemblance here to the excitement generated in the 1960s and 1970s about the possibility of combinations of chemotherapy and drugs curing cancer.

The fact is HIV does its greatest damage to the blood-immune system, and that these anti-viral drugs damage the bone marrow where blood and immune cells orginate. Although in the short term, the drugs do reduce viral activity, they may add insult to an already damaged immune system in the long term.

In several studies published in 1994, AZT was compared to a placebo, with no difference in overall survival rates. In some cases, AZT caused an increase in mortality.

Recognizing that AZT monotherapy is clearly not the solution to AIDS, some of the AIDS support groups are now suggesting that aggressive combinations of almost every anti-viral drug available be tried in AIDS patients. One proposal is to stimulate the replication of immune cells, so that more copies of the HIV virus will be produced in the hope that the drugs will kill more viruses and more immune cells (both healthy and HIV infected cells).

Killing The Immune System

The problem with such combination therapies is that--in the short term--there very well could be a significant reduction in the PCR (a test for HIV viral levels) and even a temporary increase in CD4 (T-helper cells). Regular blood tests are needed to monitor the toxicity of anti-viral drugs to determine when to switch from one combination of drugs to another.

It is interesting to note that in the two most recent studies documenting that combination anti-viral drug therapy is superior to AZT monotherapy, those who had never taken an anti-viral drug had higher survival rates than those who had previously taken AZT. One reason for the better effect on these "anti-viral virgins" was that not as much drug resistance had developed in them to the antiviral drugs. The use of AZT results in the development of drug resistant strains of HIV being formed within one to two years.

Another reason the "anti-viral virgins" did better is that their immune systems may not have been previously damaged by cytotoxic anti-viral drugs such as AZT and ddI.

First Follow Our Nontoxic Protocol

Since HIV is a slow progressing disease, and since blood tests enable you to monitor the efficacy of our new HIV TREATMENT PROTOCOL, most HIV positive individuals who have not developed AIDS should consider following our nontoxic protocol first before relying on combination anti-viral drug therapy.